Eintrag weiter verarbeiten
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α
Gespeichert in:
| Zeitschriftentitel: | Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Cancer Research, 77, 2017, 1, S. 112-122 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Tian, Xi Nguyen, Minh Foote, Henry P. Caster, Joseph M. Roche, Kyle C. Peters, Christian G. Wu, Pauline Jayaraman, Lata Garmey, Edward G. Tepper, Joel E. Eliasof, Scott Wang, Andrew Z. Tian, Xi Nguyen, Minh Foote, Henry P. Caster, Joseph M. Roche, Kyle C. Peters, Christian G. Wu, Pauline Jayaraman, Lata Garmey, Edward G. Tepper, Joel E. Eliasof, Scott Wang, Andrew Z. |
|---|---|
| author |
Tian, Xi Nguyen, Minh Foote, Henry P. Caster, Joseph M. Roche, Kyle C. Peters, Christian G. Wu, Pauline Jayaraman, Lata Garmey, Edward G. Tepper, Joel E. Eliasof, Scott Wang, Andrew Z. |
| spellingShingle |
Tian, Xi Nguyen, Minh Foote, Henry P. Caster, Joseph M. Roche, Kyle C. Peters, Christian G. Wu, Pauline Jayaraman, Lata Garmey, Edward G. Tepper, Joel E. Eliasof, Scott Wang, Andrew Z. Cancer Research CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α Cancer Research Oncology |
| author_sort |
tian, xi |
| spelling |
Tian, Xi Nguyen, Minh Foote, Henry P. Caster, Joseph M. Roche, Kyle C. Peters, Christian G. Wu, Pauline Jayaraman, Lata Garmey, Edward G. Tepper, Joel E. Eliasof, Scott Wang, Andrew Z. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-15-2951 <jats:title>Abstract</jats:title> <jats:p>Novel agents are needed to improve chemoradiotherapy for locally advanced rectal cancer. In this study, we assessed the ability of CRLX101, an investigational nanoparticle–drug conjugate containing the payload camptothecin (CPT), to improve therapeutic responses as compared with standard chemotherapy. CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and murine xenograft models. CRLX101 was as potent as CPT in vitro in its ability to radiosensitize cancer cells. Evaluations in vivo demonstrated that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic efficacy by inhibiting DNA repair and HIF1α pathway activation in tumor cells. Notably, CRLX101 was more effective than oxaliplatin at enhancing the efficacy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy. Gastrointestinal toxicity was also significantly lower for CRLX101 compared with CPT when combined with radiotherapy. Our results offer a preclinical proof of concept for CRLX101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in support of ongoing clinical evaluation of this agent (LCC1315 NCT02010567). Cancer Res; 77(1); 112–22. ©2016 AACR.</jats:p> CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α Cancer Research |
| doi_str_mv |
10.1158/0008-5472.can-15-2951 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE1LTI5NTE |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE1LTI5NTE |
| institution |
DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 |
| imprint |
American Association for Cancer Research (AACR), 2017 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2017 |
| issn |
0008-5472 1538-7445 |
| issn_str_mv |
0008-5472 1538-7445 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
tian2017crlx101ananoparticledrugconjugatecontainingcamptothecinimprovesrectalcancerchemoradiotherapybyinhibitingdnarepairandhif1a |
| publishDateSort |
2017 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Research |
| source_id |
49 |
| title |
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_unstemmed |
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_full |
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_fullStr |
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_full_unstemmed |
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_short |
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_sort |
crlx101, a nanoparticle–drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting dna repair and hif1α |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/0008-5472.can-15-2951 |
| publishDate |
2017 |
| physical |
112-122 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Novel agents are needed to improve chemoradiotherapy for locally advanced rectal cancer. In this study, we assessed the ability of CRLX101, an investigational nanoparticle–drug conjugate containing the payload camptothecin (CPT), to improve therapeutic responses as compared with standard chemotherapy. CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and murine xenograft models. CRLX101 was as potent as CPT in vitro in its ability to radiosensitize cancer cells. Evaluations in vivo demonstrated that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic efficacy by inhibiting DNA repair and HIF1α pathway activation in tumor cells. Notably, CRLX101 was more effective than oxaliplatin at enhancing the efficacy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy. Gastrointestinal toxicity was also significantly lower for CRLX101 compared with CPT when combined with radiotherapy. Our results offer a preclinical proof of concept for CRLX101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in support of ongoing clinical evaluation of this agent (LCC1315 NCT02010567). Cancer Res; 77(1); 112–22. ©2016 AACR.</jats:p> |
| container_issue |
1 |
| container_start_page |
112 |
| container_title |
Cancer Research |
| container_volume |
77 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348312409473032 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:08:44.356Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=CRLX101%2C+a+Nanoparticle%E2%80%93Drug+Conjugate+Containing+Camptothecin%2C+Improves+Rectal+Cancer+Chemoradiotherapy+by+Inhibiting+DNA+Repair+and+HIF1%CE%B1&rft.date=2017-01-01&genre=article&issn=1538-7445&volume=77&issue=1&spage=112&epage=122&pages=112-122&jtitle=Cancer+Research&atitle=CRLX101%2C+a+Nanoparticle%E2%80%93Drug+Conjugate+Containing+Camptothecin%2C+Improves+Rectal+Cancer+Chemoradiotherapy+by+Inhibiting+DNA+Repair+and+HIF1%CE%B1&aulast=Wang&aufirst=Andrew+Z.&rft_id=info%3Adoi%2F10.1158%2F0008-5472.can-15-2951&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348312409473032 |
| author | Tian, Xi, Nguyen, Minh, Foote, Henry P., Caster, Joseph M., Roche, Kyle C., Peters, Christian G., Wu, Pauline, Jayaraman, Lata, Garmey, Edward G., Tepper, Joel E., Eliasof, Scott, Wang, Andrew Z. |
| author_facet | Tian, Xi, Nguyen, Minh, Foote, Henry P., Caster, Joseph M., Roche, Kyle C., Peters, Christian G., Wu, Pauline, Jayaraman, Lata, Garmey, Edward G., Tepper, Joel E., Eliasof, Scott, Wang, Andrew Z., Tian, Xi, Nguyen, Minh, Foote, Henry P., Caster, Joseph M., Roche, Kyle C., Peters, Christian G., Wu, Pauline, Jayaraman, Lata, Garmey, Edward G., Tepper, Joel E., Eliasof, Scott, Wang, Andrew Z. |
| author_sort | tian, xi |
| container_issue | 1 |
| container_start_page | 112 |
| container_title | Cancer Research |
| container_volume | 77 |
| description | <jats:title>Abstract</jats:title> <jats:p>Novel agents are needed to improve chemoradiotherapy for locally advanced rectal cancer. In this study, we assessed the ability of CRLX101, an investigational nanoparticle–drug conjugate containing the payload camptothecin (CPT), to improve therapeutic responses as compared with standard chemotherapy. CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and murine xenograft models. CRLX101 was as potent as CPT in vitro in its ability to radiosensitize cancer cells. Evaluations in vivo demonstrated that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic efficacy by inhibiting DNA repair and HIF1α pathway activation in tumor cells. Notably, CRLX101 was more effective than oxaliplatin at enhancing the efficacy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy. Gastrointestinal toxicity was also significantly lower for CRLX101 compared with CPT when combined with radiotherapy. Our results offer a preclinical proof of concept for CRLX101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in support of ongoing clinical evaluation of this agent (LCC1315 NCT02010567). Cancer Res; 77(1); 112–22. ©2016 AACR.</jats:p> |
| doi_str_mv | 10.1158/0008-5472.can-15-2951 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE1LTI5NTE |
| imprint | American Association for Cancer Research (AACR), 2017 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2017 |
| institution | DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1 |
| issn | 0008-5472, 1538-7445 |
| issn_str_mv | 0008-5472, 1538-7445 |
| language | English |
| last_indexed | 2024-03-01T18:08:44.356Z |
| match_str | tian2017crlx101ananoparticledrugconjugatecontainingcamptothecinimprovesrectalcancerchemoradiotherapybyinhibitingdnarepairandhif1a |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 112-122 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Research |
| source_id | 49 |
| spelling | Tian, Xi Nguyen, Minh Foote, Henry P. Caster, Joseph M. Roche, Kyle C. Peters, Christian G. Wu, Pauline Jayaraman, Lata Garmey, Edward G. Tepper, Joel E. Eliasof, Scott Wang, Andrew Z. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-15-2951 <jats:title>Abstract</jats:title> <jats:p>Novel agents are needed to improve chemoradiotherapy for locally advanced rectal cancer. In this study, we assessed the ability of CRLX101, an investigational nanoparticle–drug conjugate containing the payload camptothecin (CPT), to improve therapeutic responses as compared with standard chemotherapy. CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and murine xenograft models. CRLX101 was as potent as CPT in vitro in its ability to radiosensitize cancer cells. Evaluations in vivo demonstrated that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic efficacy by inhibiting DNA repair and HIF1α pathway activation in tumor cells. Notably, CRLX101 was more effective than oxaliplatin at enhancing the efficacy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy. Gastrointestinal toxicity was also significantly lower for CRLX101 compared with CPT when combined with radiotherapy. Our results offer a preclinical proof of concept for CRLX101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in support of ongoing clinical evaluation of this agent (LCC1315 NCT02010567). Cancer Res; 77(1); 112–22. ©2016 AACR.</jats:p> CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α Cancer Research |
| spellingShingle | Tian, Xi, Nguyen, Minh, Foote, Henry P., Caster, Joseph M., Roche, Kyle C., Peters, Christian G., Wu, Pauline, Jayaraman, Lata, Garmey, Edward G., Tepper, Joel E., Eliasof, Scott, Wang, Andrew Z., Cancer Research, CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α, Cancer Research, Oncology |
| title | CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_full | CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_fullStr | CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_full_unstemmed | CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_short | CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| title_sort | crlx101, a nanoparticle–drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting dna repair and hif1α |
| title_unstemmed | CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/0008-5472.can-15-2951 |